Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
05 feb 2009 - 08:02
Statutaire naam
Crucell N.V.
Titel
Crucell Announces Profits for Full Year 2008
Bericht
Leiden, The Netherlands (February 5, 2009) – Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced its financial results for the fourth quarter and full year 2008, based on International Financial Reporting Standards (IFRS). These financial results are unaudited.
Highlights:
• Crucell achieved profitability for the fourth quarter as well as for the full year; net profit in 2008 was €14.6 million, compared to a net loss of €42.9 million in 2007. This amounted to €0.22 net profit per share, compared to a net loss per share of €0.66 in 2007.
• On January 7th, 2009 Crucell announced that it was in friendly discussions with Wyeth regarding a potential combination of the two companies. On January 26th, 2009 Crucell announced that Wyeth withdrew from these discussions.
• In 2008 Crucell more than doubled the production of its pentavalent children’s vaccine Quinvaxem®. In 2008 supranational organizations awarded Crucell additional contracts for supplies of Quinvaxem® and Hepavax-Gene® for the period 2008 - 2009, bringing the total for the period 2007 - 2009 to $0.5 billion.
• Crucell announced that Chinese authorities have approved Hepavax-Gene® for use in the private vaccine market in China.
• Crucell announced that its monoclonal antibody (mAb) directed against a broad range of influenza virus strains has strongly outperformed oseltamivir, an anti-influenza drug, in preclinical tests.
• In 2008 Crucell’s human monoclonal antibody combination against rabies and novel vaccine against tuberculosis both entered into Phase II clinical testing.
• In 2008 DSM and Crucell announced a series of important advances in antibody production using PER.C6® technology platform. For example, a PER.C6® human cell line and proprietary XD™ technology were employed to achieve a record yield of over 27 grams per liter of IgG antibodies.
• Crucell announced that its PER.C6® technology licensee Ark Therapeutics has entered a Phase III study w
Datum laatste update: 24 februari 2026